49 results on '"Le-Petross, Huong T"'
Search Results
2. ACR Appropriateness Criteria® Evaluation of Nipple Discharge: 2022 Update
- Author
-
Sanford, Matthew F., Slanetz, Priscilla J., Lewin, Alana A., Baskies, Arnold M., Bozzuto, Laura, Branton, Susan A., Hayward, Jessica H., Le-Petross, Huong T., Newell, Mary S., Scheel, John R., Sharpe, Richard E., Jr., Ulaner, Gary A., Weinstein, Susan P., and Moy, Linda
- Published
- 2022
- Full Text
- View/download PDF
3. Prospective Comparison of Synthesized Mammography with DBT and Full-Field Digital Mammography with DBT Uncovers Recall Disagreements That may Impact Cancer Detection
- Author
-
Huang, Monica L., Hess, Kenneth, Ma, Junsheng, Santiago, Lumarie, Scoggins, Marion E., Arribas, Elsa, Adrada, Beatriz E., Le-Petross, Huong T., Leung, Jessica W.T., Yang, Wei, Geiser, William, and Candelaria, Rosalind P.
- Published
- 2022
- Full Text
- View/download PDF
4. Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer
- Author
-
Candelaria, Rosalind P., Adrada, Beatriz E., Lane, Deanna L., Rauch, Gaiane M., Moulder, Stacy L., Thompson, Alastair M., Bassett, Roland L., Arribas, Elsa M., Le-Petross, Huong T., Leung, Jessica W.T., Spak, David A., Ravenberg, Elizabeth E., White, Jason B., Valero, Vicente, and Yang, Wei T.
- Published
- 2022
- Full Text
- View/download PDF
5. ACR Appropriateness Criteria® Imaging of the Axilla
- Author
-
Le-Petross, Huong T., Slanetz, Priscilla J., Lewin, Alana A., Bao, Jean, Dibble, Elizabeth H., Golshan, Mehra, Hayward, Jessica H., Kubicky, Charlotte D., Leitch, A. Marilyn, Newell, Mary S., Prifti, Christine, Sanford, Matthew F., Scheel, John R., Sharpe, Richard E., Jr., Weinstein, Susan P., and Moy, Linda
- Published
- 2022
- Full Text
- View/download PDF
6. ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density
- Author
-
Weinstein, Susan P., Slanetz, Priscilla J., Lewin, Alana A., Battaglia, Tracy, Chagpar, Anees B., Dayaratna, Sandra, Dibble, Elizabeth H., Goel, Mita Sanghavi, Hayward, Jessica H., Kubicky, Charlotte D., Le-Petross, Huong T., Newell, Mary S., Sanford, Matthew F., Scheel, John R., Vincoff, Nina S., Yao, Katherine, and Moy, Linda
- Published
- 2021
- Full Text
- View/download PDF
7. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)
- Author
-
Abdelhafez, Abeer H., Musall, Benjamin C., Adrada, Beatriz E., Hess, KennethR., Son, Jong Bum, Hwang, Ken-Pin, Candelaria, Rosalind P., Santiago, Lumarie, Whitman, Gary J., Le-Petross, Huong T., Moseley, Tanya W., Arribas, Elsa, Lane, Deanna L., Scoggins, Marion E., Leung, Jessica W. T., Mahmoud, Hagar S., White, Jason B., Ravenberg, Elizabeth E., Litton, Jennifer K., Valero, Vicente, Wei, Peng, Thompson, Alastair M., Moulder, Stacy L., Pagel, Mark D., Ma, Jingfei, Yang, Wei T., and Rauch, Gaiane M.
- Published
- 2021
- Full Text
- View/download PDF
8. ACR Appropriateness Criteria® Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women
- Author
-
Lewin, Alana A., Moy, Linda, Baron, Paul, Didwania, Aarati D., diFlorio-Alexander, Roberta M., Hayward, Jessica H., Le-Petross, Huong T., Newell, Mary S., Rewari, Amar, Scheel, John R., Stuckey, Ashley R., Suh, W. Warren, Ulaner, Gary A., Vincoff, Nina S., Weinstein, Susan P., and Slanetz, Priscilla J.
- Published
- 2019
- Full Text
- View/download PDF
9. Robotic DIEP Patient Selection: Analysis of CT Angiography
- Author
-
Kurlander, David E., Le-Petross, Huong T., Shuck, John W., Butler, Charles E., and Selber, Jesse C.
- Published
- 2021
- Full Text
- View/download PDF
10. ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer
- Author
-
Postlewait, Lauren M., Teshome, Mediget, Adesoye, Taiwo, DeSnyder, Sarah M., Lim, Bora, Kuerer, Henry M., Bedrosian, Isabelle, Sun, Susie X., Woodward, Wendy A., Le-Petross, Huong T., Valero, Vicente, Ueno, Naoto T., and Lucci, Anthony
- Published
- 2021
- Full Text
- View/download PDF
11. Screening Modalities for Women at Intermediate and High Risk for Breast Cancer
- Author
-
Spak, David A. and Le-Petross, Huong T.
- Published
- 2019
- Full Text
- View/download PDF
12. Effect of Mammography on Marker Clip Migration After Stereotactic-Guided Core Needle Breast Biopsy
- Author
-
Le-Petross, Huong T., Hess, Kenneth R., Knudtson, John D., Lane, Deanna L., Moseley, Tanya W., Geiser, William R., and Whitman, Gary J.
- Published
- 2017
- Full Text
- View/download PDF
13. Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer.
- Author
-
Xu, Zhan, Rauch, David E., Mohamed, Rania M., Pashapoor, Sanaz, Zhou, Zijian, Panthi, Bikash, Son, Jong Bum, Hwang, Ken-Pin, Musall, Benjamin C., Adrada, Beatriz E., Candelaria, Rosalind P., Leung, Jessica W. T., Le-Petross, Huong T. C., Lane, Deanna L., Perez, Frances, White, Jason, Clayborn, Alyson, Reed, Brandy, Chen, Huiqin, and Sun, Jia
- Subjects
DEEP learning ,DIGITAL image processing ,MATHEMATICAL models ,MAGNETIC resonance imaging ,CANCER patients ,TUMOR classification ,THEORY ,RESEARCH funding ,SENSITIVITY & specificity (Statistics) ,BREAST tumors - Abstract
Simple Summary: Quantitative image analysis of cancers requires accurate tumor segmentation that is often performed manually. In this study, we developed a deep learning model with a self-configurable nnU-Net for fully automated tumor segmentation on serially acquired dynamic contrast-enhanced MRI images of triple-negative breast cancer. In an independent testing dataset, our nnU-Net-based deep learning model performed automated tumor segmentation with a Dice similarity coefficient of 93% and a sensitivity of 96%. Accurate tumor segmentation is required for quantitative image analyses, which are increasingly used for evaluation of tumors. We developed a fully automated and high-performance segmentation model of triple-negative breast cancer using a self-configurable deep learning framework and a large set of dynamic contrast-enhanced MRI images acquired serially over the patients' treatment course. Among all models, the top-performing one that was trained with the images across different time points of a treatment course yielded a Dice similarity coefficient of 93% and a sensitivity of 96% on baseline images. The top-performing model also produced accurate tumor size measurements, which is valuable for practical clinical applications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).
- Author
-
Boughey, Judy C., Rosenkranz, Kari M., Ballman, Karla V., McCall, Linda, Haffty, Bruce G., Cuttino, Laurie W., Kubicky, Charlotte D., Le-Petross, Huong T., Giuliano, Armando E., Van Zee, Kimberly J., Hunt, Kelly K., Hahn, Olwen M., Carey, Lisa A., and Partridge, Ann H.
- Published
- 2023
- Full Text
- View/download PDF
15. Assessment, Complications, and Surveillance of Breast Implants: Making Sense of 2022 FDA Breast Implant Guidance.
- Author
-
Le-Petross, Huong T., Scoggins, Marion E., and Clemens, Mark W.
- Subjects
BREAST surgery ,MAMMOGRAMS ,PROSTHETICS ,SILICONES ,ULTRASONIC imaging ,RADIOLOGISTS ,ARTIFICIAL implants ,SURGICAL complications ,MAGNETIC resonance imaging ,MAMMAPLASTY ,BREAST implants ,MEDICAL protocols ,RISK assessment ,PSYCHOSOCIAL factors ,NEW product development laws ,NEW product development ,PATIENT education ,MEDICAL equipment ,PRODUCT safety - Abstract
As more information about the potential risks and complications related to breast implants has become available, the United States Food and Drug Administration (FDA) has responded by implementing changes to improve patient education, recalling certain devices and updating the recommendations for screening for silicone implant rupture. In addition to staying up-to-date with FDA actions and guidance, radiologists need to maintain awareness about the types of implants they may see, breast reconstruction techniques including the use of acellular dermal matrix, and the multimodality imaging of implants and their complications. Radiologists should also be familiar with some key differences between the updated FDA guidelines for implant screening and the imaging recommendations from the American College of Radiology Appropriateness Criteria. The addition of US as an acceptable screening exam for silicone implant rupture by the FDA is one of the most notable changes that has potentially significant implications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Predicting the Extent of Nodal Disease in Early-Stage Breast Cancer
- Author
-
Caudle, Abigail S., Kuerer, Henry M., Le-Petross, Huong T., Yang, Wei, Yi, Min, Bedrosian, Isabelle, Krishnamurthy, Savitri, Fornage, Bruno D., Hunt, Kelly K., and Mittendorf, Elizabeth A.
- Published
- 2014
- Full Text
- View/download PDF
17. The need for MRI before breast-conserving surgery
- Author
-
Le-Petross, Huong T. and Stafford, R. Jason
- Published
- 2009
- Full Text
- View/download PDF
18. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings
- Author
-
Yang, Wei T., Le-Petross, Huong T., Macapinlac, Homer, Carkaci, Selin, Gonzalez-Angulo, Ana M., Dawood, Shaheenah, Resetkova, Erika, Hortobagyi, Gabriel N., and Cristofanilli, Massimo
- Published
- 2008
- Full Text
- View/download PDF
19. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial
- Author
-
Boughey, Judy C., Suman, Vera J., Mittendorf, Elizabeth A., Ahrendt, Gretchen M., Wilke, Lee G., Taback, Bret, Leitch, Marilyn A., Kuerer, Henry M., Bowling, Monet, Flippo-Morton, Teresa S., Byrd, David R., Ollila, David W., Julian, Thomas B., McLaughlin, Sarah A., McCall, Linda, Symmans, Fraser W., Le-Petross, Huong T., Haffty, Bruce G., Buchholz, Thomas A., Nelson, Heidi, and Hunt, Kelly K.
- Published
- 2013
- Full Text
- View/download PDF
20. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer
- Author
-
Le-Petross, Huong T., Whitman, Gary J., Atchley, Deanne P., Yuan, Ying, Gutierrez-Barrera, Angelica, Hortobagyi, Gabriel N., Litton, Jennifer K., and Arun, Banu K.
- Published
- 2011
- Full Text
- View/download PDF
21. Cytologically Proven Axillary Lymph Node Metastases Are Eradicated in Patients Receiving Preoperative Chemotherapy With Concurrent Trastuzumab for HER2-Positive Breast Cancer
- Author
-
Dominici, Laura S., Negron Gonzalez, Viviana M., Buzdar, Aman U., Lucci, Anthony, Mittendorf, Elizabeth A., Le-Petross, Huong T., Babiera, Gildy V., Meric-Bernstam, Funda, Hunt, Kelly K., and Kuerer, Henry M.
- Published
- 2010
- Full Text
- View/download PDF
22. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer.
- Author
-
Postlewait, Lauren M., Teshome, Mediget, Adesoye, Taiwo, DeSnyder, Sarah M., Lim, Bora, Kuerer, Henry M., Bedrosian, Isabelle, Sun, Susie X., Woodward, Wendy A., Le-Petross, Huong T., Valero, Vicente, Ueno, Naoto T., and Lucci, Anthony
- Abstract
Background: Nearly one-third of patients with inflammatory breast cancer (IBC) present with de novo stage IV disease. There are limited data on frequency and clinical outcomes of contralateral axillary metastasis (CAM) in IBC with no consensus diagnostic and treatment guidelines. Patients and Methods: Frequency of synchronous CAM was calculated in unilateral IBC patients at a single center (10/2004–6/2019). Clinicopathologic variables, diagnostic evaluation, treatment received, and overall survival (OS) were assessed and compared. Results: Of 588 unilateral IBC patients, 49 (8.3%) had synchronous CAM. Of these, 32 (65.3%) also presented with metastatic disease at another distant site. CAM was not associated with age, tumor laterality, breast cancer subtype, grade, or cN stage (p > 0.05). The sensitivity/specificity to detect CAM was as follows: mammography (18.2%/99.2%), ultrasound (92.3%/95.5%), PET (90.1/99.1%), and MRI (76.0%/98.6%). Following systemic therapy, 22 patients had contralateral axillary surgery, and 18 received adjuvant contralateral nodal radiation. On multivariable analysis including tumor receptor subtypes, patients with stage IV-isolated CAM has statistically similar survival to stage III patients (HR 1.37, 95% CI 0.70–2.69, p = 0.36). Patients with Stage IV non-CAM (HR 2.18, 95% CI 1.66–2.85, p < 0.001) and stage IV-CAM plus other distant metastasis (HR 2.57, 95% CI 1.59–4.16, p < 0.001) had higher risk of death (reference: stage III disease). Conclusions: CAM in IBC was diagnosed in 8.3% of patients at presentation and was best identified by ultrasound and PET. We recommend routine contralateral axillary ultrasound as part of staging for all IBC patients. Diagnosis of CAM is a key first step toward much-needed prospective clinical trials evaluating management and outcomes of CAM in IBC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Inflammatory breast cancer appearance at presentation is associated with overall survival.
- Author
-
Balema, Wintana, Liu, Diane, Shen, Yu, El‐Zein, Randa, Debeb, Bisrat G., Kai, Megumi, Overmoyer, Beth, Miller, Kathy D., Le‐Petross, Huong T., Ueno, Naoto T., and Woodward, Wendy A.
- Subjects
BREAST cancer ,OVERALL survival ,SYMPTOMS ,TUMOR classification ,FISHER exact test - Abstract
Background: Inflammatory breast cancer (IBC) is a clinical diagnosis. Here, we examined the association of a "classic" triad of clinical signs, swollen involved breast, nipple change, and diffuse skin change, with overall survival (OS). Method: Breast medical photographs from patients enrolled on a prospective IBC registry were scored by two independent reviewers as classic (triad above), not classic, and difficult to assign. Chi‐squared test, Fisher's exact test, and Wilcoxon rank‐sum test were used to assess differences between patient groups. Kaplan–Meier estimates and the log‐rank test and Cox proportional hazard regression were used to assess the OS. Results: We analyzed 245 IBC patients with median age 54 (range 26–81), M0 versus M1 status (157 and 88 patients, respectively). The classic triad was significantly associated with smoking, post‐menopausal status, and metastatic disease at presentation (p = 0.002, 0.013, and 0.035, respectively). Ten‐year actuarial OS for not classic and difficult to assign were not significantly different and were grouped for further analyses. Ten‐year OS was 29.7% among patients with the classic sign triad versus 57.2% for non‐classic (p < 0.0001). The multivariate Cox regression model adjusting for clinical staging (p < 0.0001) and TNBC status (<0.0001) demonstrated classic presentation score significantly associated with poorer OS time (HR 2.6, 95% CI 1.7–3.9, p < 0.0001). Conclusions: A triad of classic IBC signs independently predicted OS in patients diagnosed with IBC. Further work is warranted to understand the biology related to clinical signs and further extend the understanding of physical examination findings in IBC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Breast density, MR imaging biomarkers, and breast cancer risk.
- Author
-
Porembka, Jessica H., Ma, Jingfei, and Le‐Petross, Huong T.
- Subjects
BREAST tumor risk factors ,BIOMARKERS ,BREAST physiology ,MAMMOGRAMS ,MAGNETIC resonance imaging ,RISK assessment - Abstract
Mammographic breast density and various breast MRI features are imaging biomarkers that can predict a woman's future risk of breast cancer. While mammographic density (MD) has been established as an independent risk factor for the development of breast cancer, MD assessment methods need to be accurate and reproducible for widespread clinical use in stratifying patients based on their risk. In addition, a number of breast MRI biomarkers using contrast‐enhanced and noncontrast‐enhanced techniques are also being investigated as risk predictors. The validation and standardization of these breast MRI biomarkers will be necessary for population‐based clinical implementation of patient risk stratification, as well. This review provides an update on MD assessment methods, breast MRI biomarkers, and their ability to predict breast cancer risk. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Application of Three-Dimensional Printed Vascular Modeling as a Perioperative Guide to Perforator Mapping and Pedicle Dissection during Abdominal Flap Harvest for Breast Reconstruction.
- Author
-
DeFazio, Michael V., Arribas, Elsa M., Ahmad, Faisal I., Le-Petross, Huong T., Liu, Jun, Chu, Carrie K., Santiago, Lumarie, and Clemens, Mark W.
- Subjects
PERFORATOR flaps (Surgery) ,MAMMAPLASTY ,FREE flaps ,THREE-dimensional printing ,COMPUTED tomography ,ANGIOGRAPHY - Abstract
Background Advancements in three-dimensional (3D) printing have enabled production of patient-specific guides to aid perforator mapping and pedicle dissection during abdominal flap harvest. We present our early experience using this tool to navigate deep inferior epigastric artery (DIEA) topography and evaluate its impact on operative efficiency and clinical outcomes. Patients and Methods Between January 2013 and December 2018, a total of 50 women underwent computed tomographic angiography (CTA)-guided perforator mapping prior to abdominal flap breast reconstruction, with (n = 9) and without (n = 41) 3D-printed vascular modeling (3DVM). Models were assessed for their accuracy in identifying perforator location and source-vessel anatomy, as determined by operative findings from 18 hemi-abdomens. The margin of error (MOE) for perforator localization using 3DVM was calculated and compared with CTA-derived measurements for the same patients. Flap harvest times, outcomes, and complications for patients who were preoperatively mapped using 3DVM versus CTA alone were analyzed. Results Overall, complete concordance was observed between 3DVM and operative findings with regards to perforator number, source-vessel origin, and DIEA branching pattern. By comparison, CTA interpretation of these parameters inaccurately identified branching pattern and perforator source-vessel origin in 28 and 33% of hemi-abdomens, respectively (p = 0.045 and p = 0.02). Compared with operative measurements, the average MOE for perforator localization using 3DVM was significantly lower than that obtained from CTA alone (0.81 vs. 8.71 mm, p < 0.0001). Reference of 3D-printed models, intraoperatively, was associated with a mean reduction in flap harvest time by 21 minutes (60.7 vs. 81.7 minutes, p < 0.001). Although not statistically significant, rates of perforator-level injury, microvascular insufficiency, and fat necrosis were lower among patients mapped using 3DVM. Conclusion The results of this study support the accuracy of 3DVM for identifying DIEA topography and perforator location. Application of this technology may translate to enhanced operative efficiency and fewer perfusion-related complications for patients undergoing abdominal free flap breast reconstruction. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. ACR Appropriateness Criteria® Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.
- Author
-
Expert Panel on Breast Imaging, Lewin, Alana A, Moy, Linda, Baron, Paul, Didwania, Aarati D, diFlorio-Alexander, Roberta M, Hayward, Jessica H, Le-Petross, Huong T, Newell, Mary S, Rewari, Amar, Scheel, John R, Stuckey, Ashley R, Suh, W Warren, Ulaner, Gary A, Vincoff, Nina S, Weinstein, Susan P, and Slanetz, Priscilla J
- Abstract
As the proportion of women diagnosed with early stage breast cancer increases, the role of imaging for staging and surveillance purposes is considered. National and international guidelines discourage the use of staging imaging for asymptomatic patients newly diagnosed with stage 0 to II breast cancer, even if there is nodal involvement, as unnecessary imaging can delay care and affect outcomes. In asymptomatic patients with a history of stage I breast cancer that received treatment for curative intent, there is no role for imaging to screen for distant recurrences. However, routine surveillance with an annual mammogram is the only imaging test that should be performed to detect an in-breast recurrence or a new primary breast cancer in women with a history of stage I breast cancer. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. Mammographic breast density is associated with the development of contralateral breast cancer.
- Author
-
Raghavendra, Akshara, Sinha, Arup K., Le‐Petross, Huong T., Garg, Naveen, Hsu, Limin, Patangan, Modesto, Bevers, Therese Bartholomew, Shen, Yu, Banu, Arun, Tripathy, Debu, Bedrosian, Isabelle, Barcenas, Carlos H., Le-Petross, Huong T, and Patangan, Modesto Jr
- Subjects
BREAST cancer patients ,BREAST cancer diagnosis ,BREAST cancer chemotherapy ,MULTIVARIABLE testing ,BREAST cancer risk factors - Abstract
Background: Women with dense mammographic breast density (BD) have a 2-fold increased risk of developing primary breast cancer (BC). The authors hypothesized that dense mammographic BD also is associated with an increased risk of developing contralateral breast cancer (CBC).Methods: Among female patients treated at The University of Texas MD Anderson Cancer Center for sporadic, AJCC stage I to stage III BC between January 1997 and December 2012, the authors identified patients who had developed metachronous CBC (cases) and selected 1:2 matched controls who did not develop CBC using incidence density sampling, matched on attainted age, year of diagnosis, and hormone receptor status of the first BC. Mammographic BD, assessed at the time of first BC diagnosis, was categorized as "nondense" (American College of Radiology breast categories of fatty or scattered density) or "dense" (American College of Radiology categories of heterogeneously dense or extremely dense). Multivariable conditional logistic regression models were used for statistical analysis.Results: A total of 229 cases and 451 controls were evaluated. Among the cases, approximately 39.3% had nondense breast tissue and 60.7% had dense breast tissue. Among controls, approximately 48.3% had nondense breast tissue and 51.7% had dense breast tissue. After adjustment for potential prognostic risk factors for BC, the odds of developing CBC were found to be significantly higher for patients with dense breasts (odds ratio, 1.80; 95% confidence interval, 1.22-2.64 [P<.01]) than for those with nondense breasts. Patients who received chemotherapy or endocrine therapy were less likely to develop CBC.Conclusions: In women with primary BC, mammographic BD appears to be a risk factor for the development of CBC. Cancer 2017;123:1935-1940. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. ACR Appropriateness Criteria® Breast Pain.
- Author
-
Expert Panel on Breast Imaging:, Holbrook, Anna I, Moy, Linda, Akin, Esma A, Baron, Paul, Didwania, Aarati D, Heller, Samantha L, Le-Petross, Huong T, Lewin, Alana A, Lourenco, Ana P, Mehta, Tejas S, Niell, Bethany L, Slanetz, Priscilla J, Stuckey, Ashley R, Tuscano, Daymen S, Vincoff, Nina S, Weinstein, Susan P, and Newell, Mary S
- Abstract
Breast pain is a common complaint. However, in the absence any accompanying suspicious clinical finding (eg, lump or nipple discharge), the association with malignancy is very low (0%-3.0%). When malignancy-related, breast pain tends to be focal (less than one quadrant) and persistent. Pain that is clinically insignificant (nonfocal [greater than one quadrant], diffuse, or cyclical) requires no imaging beyond what is recommended for screening. In cases of pain that is clinically significant (focal and noncyclical), imaging with mammography, digital breast tomosynthesis (DBT), and ultrasound are appropriate, depending on the patient's age. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast.
- Author
-
Expert Panel on Breast Imaging:, Niell, Bethany L, Lourenco, Ana P, Moy, Linda, Baron, Paul, Didwania, Aarati D, diFlorio-Alexander, Roberta M, Heller, Samantha L, Holbrook, Anna I, Le-Petross, Huong T, Lewin, Alana A, Mehta, Tejas S, Slanetz, Priscilla J, Stuckey, Ashley R, Tuscano, Daymen S, Ulaner, Gary A, Vincoff, Nina S, Weinstein, Susan P, and Newell, Mary S
- Abstract
Although the majority of male breast problems are benign with gynecomastia as the most common etiology, men with breast symptoms and their referring providers are typically concerned about whether or not it is due to breast cancer. If the differentiation between benign disease and breast cancer cannot be made on the basis of clinical findings, or if the clinical presentation is suspicious, imaging is indicated. The panel recommends the following approach to breast imaging in symptomatic men. In men with clinical findings consistent with gynecomastia or pseudogynecomastia, no imaging is routinely recommended. If an indeterminate breast mass is identified, the initial recommended imaging study is ultrasound in men younger than age 25, and mammography or digital breast tomosynthesis in men age 25 and older. If physical examination is suspicious for a male breast cancer, mammography or digital breast tomosynthesis is recommended irrespective of patient age. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. From the lab to the clinic: Lessons learned from a translational working group.
- Author
-
Lynch, Thomas, Basila, Desiree, Schnitt, Stuart J., Marks, Jeffrey R, Strand, Siri H, Hyslop, Terry, Badve, Sunil S., Watson, Mark A, Le-Petross, Huong T., Grimm, Lars, West, Robert B., Weiss, Anna, Rapperport, Anna, King, Lorraine, Factor, Rachel E., Ryser, Marc D, Partridge, Ann H., Hwang, Eun-Sil Shelley, Thompson, Alastair Mark, and Collyar, Deborah E.
- Published
- 2023
- Full Text
- View/download PDF
31. chapter 85 - Unknown Primary Presenting with Axillary Lymphadenopathy
- Author
-
Singletary, S. Eva, Middleton, Lavinia P., and Le-Petross, Huong T.
- Published
- 2010
- Full Text
- View/download PDF
32. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy.
- Author
-
Boughey, Judy C., Ballman, Karla V., Le-Petross, Huong T., McCall, Linda M., Mittendorf, Elizabeth A., Ahrendt, Gretchen M., Wilke, Lee G., Taback, Bret, Feliberti, Eric C., and Hunt, Kelly K.
- Abstract
Background: The American College of Surgeons Oncology Group Z1071 trial reported a false-negative rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy in women presenting with node-positive breast cancer. One proposed method to decrease the FNR is clip placement in the positive node at initial diagnosis with confirmation of clipped node resection at surgery. Methods: Z1071 was a multi-institutional trial wherein women with clinical T0-T4,N1-N2,M0 breast cancer underwent SLN surgery and axillary dissection (ALND) after neoadjuvant chemotherapy. In cases with a clip placed in the node, the clip location at surgery (SLN or ALND) was evaluated. Results: A clip was placed at initial node biopsy in 203 patients. In the 170 (83.7%) patients with cN1 disease and at least 2 SLNs resected, clip location was confirmed in 141 cases. In 107 (75.9%) patients where the clipped node was within the SLN specimen, the FNR was 6.8% (confidence interval [CI]: 1.9%-16.5%). In 34 (24.1%) cases where the clipped node was in the ALND specimen, the FNR was 19.0% (CI: 5.4%-41.9%). In cases without a clip placed (n=355) and in those where clipped node location was not confirmed at surgery (n=29), the FNR was 13.4% and 14.3%, respectively. Conclusions: Clip placement at diagnosis of node-positive disease with removal of the clipped node during SLN surgery reduces the FNR of SLN surgery after neoadjuvant chemotherapy. Clip placement in the biopsy-proven node at diagnosis and evaluation of resected specimens for the clipped node should be considered when conducting SLN surgery in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
- Author
-
Boughey, Judy C., Ballman, Karla V., Hunt, Kelly K., McCall, Linda M., Mittendorf, Elizabeth A., Ahrendt, Gretchen M., Wilke, Lee G., and Le-Petross, Huong T.
- Published
- 2015
- Full Text
- View/download PDF
34. Magnetic Resonance Imaging and Breast Ultrasonography as an Adjunct to Mammographic Screening in High-Risk Patients.
- Author
-
Le-Petross, Huong T. and Shetty, Mahesh K.
- Abstract
Screening mammography remains the standard of care for breast cancer screening of the general population and is likely to remain so in the foreseeable future. We discuss the current role of breast ultrasound and magnetic resonance imaging (MRI) in screening for breast cancer in the high-risk population. Breast ultrasound finds small cancers not seen on mammography particularly in women with dense breasts. Breast MRI has sensitivity significantly higher than that of mammography, breast ultrasound, or a combination of mammography and breast ultrasound. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
35. Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data.
- Author
-
Carkaci, Selin, Macapinlac, Homer A., Cristofanilli, Massimo, Mawlawi, Osama, Rohren, Eric, Angulo, Ana M. Gonzalez, Dawood, Shaheenah, Resetkova, Erika, Le-Petross, Huong T., and Wei-Tse Yang
- Published
- 2009
- Full Text
- View/download PDF
36. Vasectomy-related changes on sonographic examination of the scrotum.
- Author
-
Reddy, Neena M., Gerscovich, Eugenio O., Jain, Kiran A., Le-Petross, Huong T., and Brock, John M.
- Abstract
Purpose: The goal of this study was to evaluate the sonographic changes in the epididymis and testis after vasectomy using state-of-the-art high-resolution equipment.Methods: We performed a retrospective study of 30 patients with a history of vasectomy and 30 patients without who were referred for scrotal sonography for various indications over a 1-year period. After excluding findings related to acute pathology, sonographic findings for the epididymis and testis in the 2 groups were tabulated and compared.Results: The following findings had a statistically higher incidence in the vasectomy group than in the controls: thickened epididymides (53% versus 17%, p < 0.05); epididymal tubular ectasia (43% versus 7%, p < 0.001); and both of the previous 2 findings simultaneously (37% versus 7%, p < 0.01). Sperm granulomas were found in 3 patients in the vasectomy group, and none was seen in the control group. Other findings (eg, epididymal cysts) showed no statistical difference in incidence.Conclusions: We found a significantly higher incidence of thickened epididymides, epididymal tubular ectasia, a combination of both these findings, and sperm granuloma in the vasectomy group than in the controls. These findings are most likely attributable to postvasectomy obstructive changes and increased intraluminal pressure in the efferent ducts, epididymis, and vas deferens. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
37. Contributors
- Author
-
Agnese, Doreen, Allen, Kathleen Gardiner, Ashfaq, Raheela, Aversano, Thomas R., Barsky, Sanford H., Bassett, Lawrence W., Beahm, Elisabeth K., Beenken, Samuel W., Bermas, Honnie R., Bevers, Therese B., Birru, Mehret, Bland, Kirby I., Brewster, Abenaa M., Brinton, Louise A., Brock, Malcolm V., Brooks, Mai N., Buchholz, Thomas A., Chang, Helena R., Chera, Bhishamjit S., Ching, C. Denise, Chung, Maureen A., Cody, Hiram S., III, Copeland, Edward M., III, Cox, Charles E., Cristofanilli, Massimo, Curiel, David T., Cuttino, Laurie W., de la Torre, Jorge I., De Los Santos, Jennifer F., Diab, Mohammad S., Disis, Mary L., Dooley, William C., DuPont, William D., Dutt, Philip L., Eberlein, Timothy J., Edgerton, Mary, El-Tamer, Mahmoud, Farrar, William B., Fearmonti, Regina M., Folkman, M. Judah, Freedman, Gary M., Frykberg, Eric R., Gaskin, Thomas A., III, Gemignani, Mary, Gillanders, William E., Giuliano, Armando E., Goedegebuure, Peter S., Gold, Julie, Golshan, Mehra, Gradishar, William J., Grobmyer, Stephen R., Grube, Baiba J., Harichand-Herdt, Seema, Harper, J. Garrett, Hasan, Yasmin, Hohenhaus, Mary H., Hortobagyi, Gabriel N., Howard, J. Harrison, Hsu, Christopher P., Hudson, Alana G., Hunt, Kelly K., Ioan, Anamaria, Jimenez, Rafael E., Johnson, Joyce E., Kaklamani, Virginia G., Karam, Amer, Karlin, Nina J., Kass, Rena B., Kaur, Paramjeet, Kern, Kenneth A., Khan, Seema A., Kiluk, John V., Kim, Paula, Kirwan, Jessica, Klimberg, V. Suzanne, Klobocista, Merieme, Kort, Kara C., Krontiras, Helen, Kruse, E. James, Kuerer, Henry, Lee, Jane W., Leitch, A. Marilyn, Le-Petross, Huong T., Lightsey, Judith L., Ligibel, Jennifer A., Lind, D. Scott, Lipkowitz, Stanley, Long, James N., Love, Richard, Lu, Hailing, Lynch, Henry T., Lynch, Jane, Mahoney, Mary, Mancino, Anne T., Marcus, Joseph N., Marks, Lawrence B., Masood, Shahla, Massoll, Nicole, McCraw, John B., McLoughlin, James, Meguid, Michael M., Mendenhall, Nancy P., Mendenhall, William M., Mendez, Jane, Middleton, Lavinia P., Miller, Michael J., Moore-Higgs, Giselle J., Moulton, Anne W., Mrozek, Ewa, Nabell, Lisle, Nam, Jiho, Niederhuber, John E., Numann, Patricia J., Oler, Albert, O'Regan, Ruth, Page, David L., Palazzo, Juan P., Partridge, Ann H., Peters, Sara B., Hoang Pham, John Dung, Phan, Vy, Pollock, Raphael E., Port, Elisa R., Potter, David, Povoski, Stephen P., Prati, Raquel, Press, Michael F., Price, Janet E., Puleo, Christopher A., Recht, Abram, Reeves, Katherine W., Reuben, James M., Romrell, Lynn J., Rosenbloom, Arlan L., Rubinstein, Wendy S., Ruddy, Kathryn J., Sanfilippo, Kristen, Santillan, Alfredo A., Schwartz, Gordon F., Shah, Heather, Shapiro, Charles, Shen, Angela, Shirazi, Sherin, Shyr, Yu, Silverstein, Melvin J., Simpson, Jean F., Singletary, S. Eva, Smith, Benjamin D., Snead, Felicia E., Snyder, Carrie L., Strong, Theresa V., Styblo, Toncred M., Urist, Marshall M., Uttarwar, Mohan, Vasconez, Luis O., Vicini, Frank A., Vogel, Victor G., Wakely, Paul E., Jr, Wall, Terry J., Wicha, Max, Winchester, David J., Winchester, David P., Winer, Eric P., Wood, William C., Yee, Douglas, Yung, Rex C.W., and Zelnak, Amelia
- Published
- 2010
- Full Text
- View/download PDF
38. Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review.
- Author
-
Le-Petross HT, Balema W, and Woodward WA
- Subjects
- Diagnosis, Differential, Female, Humans, Breast Neoplasms diagnosis, Inflammatory Breast Neoplasms diagnosis
- Abstract
Objective: The purpose of this narrative review is to summarize the contributors to misdiagnosis or delayed diagnosis of inflammatory breast cancer (IBC) and strategies for expedient diagnosis., Background: Patients with IBC often report the disease as initially being misdiagnosed, most commonly as mastitis., Methods: We reviewed the literature on this challenging diagnosis by using sequential PubMed search criteria including IBC breast symptoms, IBC diagnosis, and IBC imaging modalities to augment the authors' knowledge of IBC. Other references were added from the manuscripts identified in the PubMed searches and from manuscript reviewers., Conclusions: Several factors contribute to the delayed diagnosis of IBC. One important factor is that IBC is uncommon, and many generalists may not be aware of it in the differential diagnosis of breast skin symptoms. Several features of IBC contribute to the low sensitivity of mammography for its detection, and so the diagnosis is based on clinical factors and is thereby subjective. The presentation can be highly varied; classic textbook images that do not capture the range of presenting signs and symptoms across skin tones may contribute to missed diagnoses in patients with atypical presentations. In fact, the staging system of the American Joint Committee on Cancer, which requires erythema of the breast skin for diagnosis, may exclude patients with obvious global breast skin findings that are not explicitly red. We present an adapted algorithm for working up the undiagnosed inflammatory breast to ensure the timely and accurate diagnosis of IBC. We assert that frank, non-erythematous global skin signs in an enlarged breast with diffuse breast malignancy are sufficient to diagnose IBC if the timing of these signs and findings on biopsy are consistent. We further provide images of atypical IBC identified by global breast skin signs, including peau d'orange, consistent with IBC in the absence of frank erythema.
- Published
- 2021
- Full Text
- View/download PDF
39. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review.
- Author
-
Patel MM and Le-Petross HT
- Subjects
- Female, Fluorodeoxyglucose F18, Humans, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Radiopharmaceuticals, Tomography, X-Ray Computed, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Inflammatory Breast Neoplasms diagnostic imaging, Inflammatory Breast Neoplasms pathology
- Abstract
Objective: To review and discuss the rationale behind performing baseline 18-fluorodeoxyglucose positron emission tomography-computed tomography imaging for staging of inflammatory breast cancer patients., Background: In the past three decades, the epidemiology of inflammatory breast cancer has resulted in separation of this entity from other breast cancer in staging and treatment. Advances in cancer imaging from 18-fluorodeoxyglucose positron emission tomography to 18-fluorodeoxyglucose positron emission tomography-computed tomography have now allowed for anatomic and functional correlation in evaluating extent of disease in cancer patients. Furthermore, studies throughout the past two decades have highlighted how 18-fluorodeoxyglucose positron emission tomography-computed tomography may play a role in staging inflammatory breast cancer patients given the uniqueness of this entity when compared to other breast cancers., Methods: Narrative overview of the literature summarizing findings in the literature from searches in computerized databases and authoritative texts. The use of 18-fluorodeoxyglucose positron emission tomography-computed tomography with respect to regional nodal staging and distant metastasis detection in inflammatory breast cancer patients is reviewed. In addition, an overview of studies conducted to date comparing the sensitivity and specificity of 18-fluorodeoxyglucose positron emission tomography-computed tomography for baseline staging in inflammatory breast cancer patients is also provided. Therapeutic influences and effect on overall survival is discussed., Conclusions: Baseline 18-fluorodeoxyglucose positron emission tomography-computed tomography allows for more optimal nodal staging, which has implications in prognosis and treatment of inflammatory breast cancer patients. It also allows for improved detection of metastasis on baseline presentation allowing therapy to potentially target these additional sites of disease.
- Published
- 2021
- Full Text
- View/download PDF
40. Imaging Updates to Breast Cancer Lymph Node Management.
- Author
-
Chung HL, Le-Petross HT, and Leung JWT
- Subjects
- Axilla pathology, Breast pathology, Female, Humans, Lymph Node Excision, Lymph Nodes diagnostic imaging, Lymph Nodes pathology, Lymph Nodes surgery, Lymphatic Metastasis diagnostic imaging, Neoadjuvant Therapy, Neoplasm Staging, Sentinel Lymph Node Biopsy, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Breast Neoplasms therapy
- Abstract
Metastatic lymph node involvement in breast cancer is a key determinant of the overall stage of disease and prognosis. Historically, lymph node status was determined by surgery first, with adjuvant treatments determined based on the results of the final surgical pathologic analysis. While this sequence is still applicable in many cases, neoadjuvant systemic treatment (NST) is increasingly being administered as the initial treatment. In cases that demonstrate good therapeutic response to drug therapies, NST may permit the option to perform less radical surgeries subsequently. Current breast cancer treatment has become multidisciplinary, with overlapping roles from the different disciplines. As surgery may be postponed, imaging and image-guided lymph node interventions have gained importance as the primary means of lymph node assessment. Imaging enables evaluation of all regional nodal basins, including locations where surgery is not usually performed. By differentiating limited versus extensive nodal involvement, imaging findings help determine whether initial treatment should be surgical or medical. If medical treatment with NST is indicated, imaging is performed to monitor the in vivo nodal response to drug therapy and ultimately to help determine the surgical technique to perform on the basis of the final imaging findings after NST. The authors discuss the imaging features of nodal metastases and the indications and techniques for the various image-guided procedures. The relative usefulness and shortcomings of the various imaging examinations are reviewed to discuss how they can be applied when biopsy results are not available. The role of imaging in the multidisciplinary team approach is emphasized based on past clinical trials of lymph node management and recent evolving knowledge of breast cancer staging. Online supplemental material is available for this article.
© RSNA, 2021.- Published
- 2021
- Full Text
- View/download PDF
41. ACR Appropriateness Criteria ® Evaluation of the Symptomatic Male Breast.
- Author
-
Niell BL, Lourenco AP, Moy L, Baron P, Didwania AD, diFlorio-Alexander RM, Heller SL, Holbrook AI, Le-Petross HT, Lewin AA, Mehta TS, Slanetz PJ, Stuckey AR, Tuscano DS, Ulaner GA, Vincoff NS, Weinstein SP, and Newell MS
- Subjects
- Breast Neoplasms, Male diagnostic imaging, Diagnosis, Differential, Evidence-Based Medicine, Gynecomastia diagnostic imaging, Humans, Male, Societies, Medical, United States, Breast Diseases diagnostic imaging
- Abstract
Although the majority of male breast problems are benign with gynecomastia as the most common etiology, men with breast symptoms and their referring providers are typically concerned about whether or not it is due to breast cancer. If the differentiation between benign disease and breast cancer cannot be made on the basis of clinical findings, or if the clinical presentation is suspicious, imaging is indicated. The panel recommends the following approach to breast imaging in symptomatic men. In men with clinical findings consistent with gynecomastia or pseudogynecomastia, no imaging is routinely recommended. If an indeterminate breast mass is identified, the initial recommended imaging study is ultrasound in men younger than age 25, and mammography or digital breast tomosynthesis in men age 25 and older. If physical examination is suspicious for a male breast cancer, mammography or digital breast tomosynthesis is recommended irrespective of patient age. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment., (Copyright © 2018 American College of Radiology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
42. ACR Appropriateness Criteria ® Breast Pain.
- Author
-
Holbrook AI, Moy L, Akin EA, Baron P, Didwania AD, Heller SL, Le-Petross HT, Lewin AA, Lourenco AP, Mehta TS, Niell BL, Slanetz PJ, Stuckey AR, Tuscano DS, Vincoff NS, Weinstein SP, and Newell MS
- Subjects
- Age Factors, Breast Neoplasms diagnostic imaging, Diagnosis, Differential, Evidence-Based Medicine, Female, Humans, Societies, Medical, United States, Mastodynia diagnostic imaging
- Abstract
Breast pain is a common complaint. However, in the absence any accompanying suspicious clinical finding (eg, lump or nipple discharge), the association with malignancy is very low (0%-3.0%). When malignancy-related, breast pain tends to be focal (less than one quadrant) and persistent. Pain that is clinically insignificant (nonfocal [greater than one quadrant], diffuse, or cyclical) requires no imaging beyond what is recommended for screening. In cases of pain that is clinically significant (focal and noncyclical), imaging with mammography, digital breast tomosynthesis (DBT), and ultrasound are appropriate, depending on the patient's age. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment., (Copyright © 2018 American College of Radiology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
43. Role of MR Imaging in Neoadjuvant Therapy Monitoring.
- Author
-
Le-Petross HT and Lim B
- Subjects
- Breast diagnostic imaging, Contrast Media, Female, Humans, Image Enhancement methods, Treatment Outcome, Breast Neoplasms diagnostic imaging, Breast Neoplasms therapy, Magnetic Resonance Imaging methods, Neoadjuvant Therapy methods
- Abstract
Neoadjuvant chemotherapy (NAC) has become an important treatment approach for stage II/III breast cancers to downsize tumor and enable breast-conserving surgery for patients that may otherwise undergo mastectomy. MR imaging has the potential to identify early response or disease progression, enabling potential modification to NAC regimens. Detection of size and morphologic changes is better appreciated with MR imaging than other modalities and is different between molecular subtypes of breast cancer. The combination of DCE-MR imaging and DWI provides the highest sensitivity and specificity. Other new modalities such as FDG PET/MR imaging and molecular breast imaging are still undergoing research., (Published by Elsevier Inc.)
- Published
- 2018
- Full Text
- View/download PDF
44. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.
- Author
-
Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, and Woodward WA
- Abstract
National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan Welch Inflammatory Breast Cancer Research Program at The University of Texas MD Anderson Cancer Center in Houston Texas. A consensus on the clinical management of patients with IBC was discussed, summarized, and subsequently reviewed. All participants at the conference (patients, advocates, researchers, trainees, and clinicians) were queried using the MDRing electronic survey on key management issues. A summary of the expert consensus and participant voting is presented. Bilateral breast and nodal evaluation, breast magnetic resonance imaging, positron emission tomography/computed tomography, and medical photographs were endorsed as optimal. Neoadjuvant systemic therapy, modified radical mastectomy and level I and II ipsilateral axillary node dissection, post-mastectomy radiotherapy, adjuvant targeted therapy and hormonal therapy as indicated, and delayed reconstruction were agreed-upon fundamental premises of standard non-protocol-based treatment for IBC. Consideration for local-regional therapy in de novo stage IV IBC was endorsed to provide local control whenever feasible. Variation across centers and special circumstances were discussed., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2018
- Full Text
- View/download PDF
45. Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).
- Author
-
Le-Petross HT, McCall LM, Hunt KK, Mittendorf EA, Ahrendt GM, Wilke LG, Ballman KV, and Boughey JC
- Subjects
- Adult, Aged, Aged, 80 and over, Axilla pathology, Biopsy, Needle, Breast Neoplasms surgery, Chemotherapy, Adjuvant, Female, Humans, Lymphatic Metastasis pathology, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Prospective Studies, Axilla diagnostic imaging, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Lymphatic Metastasis diagnostic imaging, Ultrasonography methods
- Abstract
Objective: The purpose of this study is to determine lymph node features on axillary ultrasound (US) images obtained after neoadjuvant chemotherapy that are associated with residual nodal disease in patients with initial biopsy-proven node-positive breast cancer., Subjects and Methods: All patients had axillary US performed after neoadjuvant chemotherapy. Axillary US images were centrally reviewed for lymph node size, cortical thickness, and cortical morphologic findings (type I indicated no visible cortex; type II, a hypoechoic cortex ≤ 3 mm; type III, a hypoechoic cortex > 3 mm; type IV, a generalized lobulated hypoechoic cortex; type V, focal hypoechoic cortical lobulation; and type VI, a totally hypoechoic node with no hilum). Lymph node characteristics were compared with final surgical pathologic findings., Results: Axillary US images obtained after neoadjuvant chemotherapy and surgical pathologic findings were available for 611 patients. Residual nodal disease was present in 373 patients (61.0%), and 238 (39.0%) had a complete nodal pathologic response. Increased cortical thickness (mean, 3.5 mm for node-positive disease vs 2.5 mm for node-negative disease) was associated with residual nodal disease. Lymph node short-axis and long-axis diameters were significantly associated with pathologic findings. Patients with nodal morphologic type I or II had the lowest rate of residual nodal disease (51 of 91 patients [56.0%] and 138 of 246 patients (56.1%), respectively), whereas those with nodal morphologic type VI had the highest rate (44 of 55 patients [80.0%]) (p = 0.004). The presence of fatty hilum was significantly associated with node-negative disease (p = 0.0013)., Conclusion: Axillary US performed after neoadjuvant chemotherapy is useful for nodal response assessment, with longer short-axis diameter, longer long-axis diameter, increased cortical thickness, and absence of fatty hilum significantly associated with residual nodal disease after neoadjuvant chemotherapy.
- Published
- 2018
- Full Text
- View/download PDF
46. MRI features of inflammatory breast cancer.
- Author
-
Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, Reed BJ, and Yang WT
- Subjects
- Adult, Aged, Contrast Media, Female, Humans, Imaging, Three-Dimensional, Inflammatory Breast Neoplasms diagnostic imaging, Mammography, Middle Aged, Retrospective Studies, Ultrasonography, Mammary, Inflammatory Breast Neoplasms diagnosis, Magnetic Resonance Imaging methods
- Abstract
Objective: The aim of this study was to evaluate the features of inflammatory breast carcinoma (IBC) on MRI compared with mammography and ultrasound and to better define the role of MRI in patients with this aggressive disease., Materials and Methods: A retrospective analysis was performed of patients with newly diagnosed IBC evaluated at a single institution between 2003 and 2008. Baseline MRI examinations were performed on a 1.5- or 3-T scanner using contrast-enhanced 3D T1-weighted gradient-echo sequences with parallel imaging. MRI findings were rated in accordance with the BI-RADS MRI lexicon established by the American College of Radiology. All patients underwent concomitant mammography and ultrasound examinations., Results: Eighty women with a clinical diagnosis of IBC were included in the study (median age, 52 years; age range, 25-78 years). MRI detected a primary breast lesion in 78 of 80 symptomatic breasts (98%) compared with 53 of 78 (68%) with mammography (p < 0.0001) and 75 of 80 (94%) with ultrasound. Of the 78 breasts with a primary lesion, the most common MRI finding was a mass or multiple masses (57/78, 73%). Masses were frequently multiple, small, and confluent (47/57, 82%); mass margins, irregular (43/57, 75%); and internal enhancement pattern, heterogeneous (47/57, 82%). Kinetic analysis revealed a delayed washout pattern in 66 of 78 tumors (85%). MRI showed skin thickening in 74 of 80 breasts (93%), whereas mammography showed skin thickening in 56 of 78 breasts (72%)., Conclusion: Multiple small, confluent, heterogeneously enhancing masses and global skin thickening are key MRI features of IBC that contribute to improved detection of a primary breast cancer and delineation of disease extent compared with mammography.
- Published
- 2011
- Full Text
- View/download PDF
47. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data.
- Author
-
Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, Dawood S, Resetkova E, Le-Petross HT, and Yang WT
- Subjects
- Adult, Aged, Breast Neoplasms pathology, Breast Neoplasms secondary, Female, Humans, Inflammation diagnostic imaging, Inflammation pathology, Lymphatic Metastasis diagnostic imaging, Middle Aged, Radionuclide Imaging, Retrospective Studies, Breast Neoplasms diagnostic imaging, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Radiopharmaceuticals, Tomography, X-Ray Computed
- Abstract
Unlabelled: Our objective was to retrospectively evaluate 18F-FDG PET/CT in the initial staging of inflammatory breast cancer (IBC)., Methods: The institutional review board waived informed consent and approved this study, which was compliant with the Health Insurance Portability and Accountability Act. The cases of 41 women with a mean age of 50 y (range, 25-71 y) and newly diagnosed IBC who underwent 18F-FDG PET/CT at diagnosis were retrospectively reviewed. All PET/CT images were analyzed visually and semiquantitatively by 2 physicians. The maximum standardized uptake value in the primary breast, regional nodes (axillary, subpectoral, supraclavicular, internal mammary), and extranodal regions was documented. The accuracy of PET/CT image interpretation was assessed by histopathologic analysis, if available; concurrent or subsequent imaging findings (contrast-enhanced CT, contrast-enhanced MRI, sonography, or PET/CT follow-up); or clinical follow-up., Results: All patients presented with unilateral IBC. PET/CT showed hypermetabolic uptake in the skin in all patients, in the affected breast in 40 (98%), in the ipsilateral axillary nodes in 37 (90%), and in the ipsilateral subpectoral nodes in 18 (44%). Twenty patients (49%) were found to have distant metastases at staging, 7 (17%) of whom were not known to have metastases before undergoing PET/CT. Disease sites included bone, liver, contralateral axilla, lung, chest wall, pelvis, and the subpectoral, supraclavicular, internal mammary, mediastinal, and abdominal nodes., Conclusion: PET/CT should be considered in the initial staging of IBC, as the technique provided valuable information on locoregional and distant disease in this preliminary retrospective study.
- Published
- 2009
- Full Text
- View/download PDF
48. Breast lymphoma: imaging findings of 32 tumors in 27 patients.
- Author
-
Yang WT, Lane DL, Le-Petross HT, Abruzzo LV, and Macapinlac HA
- Subjects
- Adult, Aged, Breast Neoplasms diagnostic imaging, Female, Humans, Lymphoma diagnostic imaging, Magnetic Resonance Imaging, Mammography, Middle Aged, Positron-Emission Tomography, Retrospective Studies, Tomography, X-Ray Computed, Ultrasonography, Breast Neoplasms diagnosis, Lymphoma diagnosis
- Abstract
Purpose: To retrospectively evaluate the imaging findings of breast lymphomas in patients who had undergone mammography, ultrasonography (US), magnetic resonance (MR) imaging, or combined positron emission tomography (PET)/computed tomography (CT) scanning., Materials and Methods: The institutional review board approved this HIPAA-compliant study and waived informed consent. Twenty-seven women who had been diagnosed with breast lymphoma (32 tumors) and had undergone preoperative imaging were identified from the surgical pathology database (mean age, 51 years; median, 55 years; range, 19-78 years at time of diagnosis). Two radiologists reviewed the mammographic, US, and MR images. One nuclear medicine physician reviewed the PET/CT scans. All available pathologic specimens were reviewed by a hematologic pathologist., Results: The mean tumor size at diagnosis was 2.9 cm (range, 1-5 cm). Seventeen tumors manifested with a palpable mass, two with diffuse enlargement of the breast, and 13 were asymptomatic. Twenty-two women underwent mammography; 24, US; one, MR imaging; and 10, PET/CT scanning. Mammograms of 25 tumors showed a noncalcified mass in 19, global asymmetry in four, focal asymmetry in one, and no abnormality in one. US of 29 tumors showed a mass in 26 and diffuse architectural distortion in three. Masses typically were irregular, hypoechoic, and hypervascular and demonstrated indistinct margins or an echogenic boundary. Dynamic contrast material-enhanced MR imaging of one tumor showed an intensely and heterogeneously enhancing mass with rapid enhancement and washout characteristics. PET/CT scans of 13 tumors showed intense diffuse hypermetabolism in 12 and response to therapy in all 12 tumors., Conclusion: The imaging findings reported in this study should alert the radiologist to a possible diagnosis of breast lymphoma., ((c) RSNA, 2007.)
- Published
- 2007
- Full Text
- View/download PDF
49. Breast MRI as a screening tool: the appropriate role.
- Author
-
Le-Petross HT
- Subjects
- Female, Humans, Magnetic Resonance Imaging, Mass Screening, Risk Factors, Sensitivity and Specificity, Breast Neoplasms diagnosis, Breast Neoplasms prevention & control
- Abstract
Magnetic resonance imaging (MRI) can detect breast cancer that is occult on mammography or ultrasound. However, although the high sensitivity of this imaging modality is desirable, its lower specificity, higher cost, variable technique and interpretation among institutions, exclusion criteria, and unproven effect on survival rate make it a less desirable screening test for the general population. Several studies have shown that using more than one imaging tool, such as MRI and mammography, increases cancer yield in high-risk patients, such as those with inherited BRCA1 and BRCA2 mutations. Recent studies show improved specificity of MRI, likely related to advances in technique and the development of interpretive guidelines.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.